Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Compounding Can't Be Justified By Price, FDA Says

Executive Summary

Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.


Related Content

FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan
FDA Backs Off From Early Citations Of Compounder Sterility Issues
Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
Turing’s Shkreli Tussels With Express Scripts About ‘Ugly, Dirty Truth’ Of Drug Pricing
Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs
Roche's Lucentis Could Get Boost From House Compounding Directives To FDA
FDA Compounding Guidances Might Cull Outsourcing List
FDA Power v. State Laws: Compounders Want Clarity On Office Use





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts